Oryzon Genomics to Conduct Insightful Virtual KOL Event
Oryzon Genomics to Host Virtual KOL Event
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), renowned for its innovations in the field of epigenetics, has announced an engaging virtual KOL event aimed at addressing the complexities of Borderline Personality Disorder (BPD). This event, scheduled for a Wednesday at 12:00 pm ET, will be expertly moderated by Dr. Michael Ropacki, the Chief Medical Officer for CNS at Oryzon.
Key Speakers and Their Contributions
The virtual event will feature a panel of distinguished experts in the domain of psychiatry. These leading figures include:
Dr. Alan F. Schatzberg
Currently serving as the Kenneth T. Norris Jr. Professor at Stanford University, Dr. Schatzberg is an eminent psychiatrist with significant contributions in psychopharmacology. His involvement as the former APA president and his research on mifepristone showcases his dedication to advancing mental health treatment.
Dr. Emil F. Coccaro
Dr. Coccaro, who holds a prestigious position at The Ohio State University, has a profound expertise in the neurobiology of aggression. His research has greatly influenced the understanding of impulsive behavior and the biological underpinnings of psychiatric disorders.
Dr. Eric Hollander
As a professor at the Albert Einstein College of Medicine, Dr. Hollander leads research initiatives centered on CNS disorders. His background in treatments for autism and OCD reveals his balanced focus on both pediatric and adult mental health conditions.
Dr. Sarah Fineberg
Dr. Fineberg is making strides in understanding the neurobiological mechanisms of BPD at Yale University. Her ongoing research seeks to bridge the gap between patient experience and neurological science, pointing towards novel therapeutic avenues.
Event Insights and Expectations
The informative session promises to delve into the pressing social and clinical issues surrounding BPD, emphasizing the lack of approved pharmacological solutions. The discussion will illuminate the pitfalls of off-label medication use along with the significance of addressing agitation and aggression in BPD therapeutics.
Oryzon aims to highlight the potential of their treatment, vafidemstat, which has shown promise as an effective therapy targeting various psychiatric conditions, including BPD, schizophrenia, and ASD. Attendees can expect insights into the intricacies of Oryzon's recent FDA interactions, along with the anticipated Phase III trial protocol for vafidemstat, namely the PORTICO-2 trial.
Live Interaction and Engagement
Following the panel discussion, a live Q&A session will give participants the opportunity to engage directly with these thought leaders. This interactive element aims to foster a collaborative dialogue about future possibilities in the treatment landscape for individuals suffering from BPD.
About Oryzon Genomics
Founded in 2000, Oryzon is a clinical-stage biopharmaceutical company with a primary focus on personalized medicine in CNS disorders and oncology. With facilities in both Barcelona and the United States, Oryzon is dedicated to the advancement of epigenetic therapies, supported by a team of highly skilled professionals in the pharmaceutical industry. Their clinical portfolio includes notable LSD1 inhibitors such as vafidemstat and iadademstat, and the company is diligently working to develop novel treatments targeting various debilitating conditions.
Understanding Vafidemstat
Vafidemstat, also referred to as ORY-2001, is an innovative oral medicine optimized for the central nervous system. This drug has demonstrated substantial potential in mitigating cognitive decline and reducing neuroinflammation, as observed in various animal studies. Through its multifaceted action, vafidemstat has been noted for its ability to balance cognitive and aggressive behaviors in preclinical models, supporting its role as a transformative intervention for psychiatric disorders.
The ongoing research into vafidemstat and its unique mechanism positions Oryzon as a frontrunner in the field of neuropharmacology, with plans for further clinical trials that could redefine treatment approaches for BPD and related conditions.
Frequently Asked Questions
What is the scheduled date and time for the KOL event?
The KOL event is set for Wednesday at 12:00 pm ET.
Who are the featured experts at the event?
The event will feature Dr. Alan F. Schatzberg, Dr. Emil F. Coccaro, Dr. Eric Hollander, and Dr. Sarah Fineberg.
What topics will be discussed during the event?
The event will focus on the challenges faced by BPD patients, pharmacological treatment options, and the potential of vafidemstat as a novel therapy.
How can one register for the event?
Interested individuals can register in advance through the associated event link.
What is vafidemstat and its significance in treatment?
Vafidemstat is an oral LSD1 inhibitor that shows promise in treating various psychiatric conditions by reducing cognitive impairment and aggression.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.